Literature DB >> 26454735

Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection.

Bas Groot Koerkamp1, Jimme K Wiggers2, Peter J Allen3, Marc G Besselink2, Leslie H Blumgart3, Olivier R C Busch2, Robert J Coelen2, Michael I D'Angelica3, Ronald P DeMatteo3, Dirk J Gouma2, T Peter Kingham3, William R Jarnagin3, Thomas M van Gulik2.   

Abstract

BACKGROUND: The aim of this study was to investigate the rate and pattern of recurrence after curative intent resection of perihilar cholangiocarcinoma (PHC). STUDY
DESIGN: Patients were included from 2 prospectively maintained databases. Recurrences were categorized by site. Time to recurrence and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method. Cox proportional hazards modeling was used to identify independent poor prognostic factors.
RESULTS: Between 1991 and 2012, 306 consecutive patients met inclusion criteria. Median overall survival was 40 months. A recurrence was diagnosed in 177 patients (58%). An initial local recurrence was found in 26% of patients: liver hilum (11%), hepaticojejunostomy (8%), liver resection margin (8%), or distal bile duct remnant (2%). An initial distant recurrence was observed in 40% of patients: retroperitoneal lymph nodes (14%), intrahepatic away from the resection margin (13%), peritoneum (12%), and lungs (8%). Only 18% of patients had an isolated initial local recurrence. The estimated overall recurrence rate was 76% at 8 years. After a recurrence-free period of 5 years, 28% of patients developed a recurrence in the next 3 years. Median RFS was 26 months. Independent prognostic factors for RFS were resection margin, lymph node status, and tumor differentiation. Only node-positive PHC precluded RFS beyond 7 years.
CONCLUSIONS: Perihilar cholangiocarcinoma will recur in most patients (76%) after resection, emphasizing the need for better adjuvant strategies. The high recurrence rate of up to 8 years justifies prolonged surveillance. Only patients with an isolated initial local recurrence (18%) may have benefited from a more extensive resection or liver transplantation. Node-positive PHC appears incurable.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26454735      PMCID: PMC4736142          DOI: 10.1016/j.jamcollsurg.2015.09.005

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  27 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma.

Authors:  A Kobayashi; S Miwa; T Nakata; S Miyagawa
Journal:  Br J Surg       Date:  2010-01       Impact factor: 6.939

Review 3.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

4.  Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival.

Authors:  T M van Gulik; J J Kloek; A T Ruys; O R C Busch; G J van Tienhoven; J S Lameris; E A J Rauws; D J Gouma
Journal:  Eur J Surg Oncol       Date:  2010-11-27       Impact factor: 4.424

5.  Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma.

Authors:  Kaori Ito; Hiromichi Ito; Peter J Allen; Mithat Gonen; David Klimstra; Michael I D'Angelica; Yuman Fong; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg       Date:  2010-04       Impact factor: 12.969

6.  Survival benefit of hepatopancreatoduodenectomy for cholangiocarcinoma in comparison to hepatectomy or pancreatoduodenectomy.

Authors:  Yuji Kaneoka; Akihiro Yamaguchi; Masatoshi Isogai; Takashi Kumada
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

7.  Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy.

Authors:  M F Gerhards; D G Gonzalez; H ten Hoopen-Neumann; T M van Gulik; L T de Wit; D J Gouma
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

8.  Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.

Authors:  Gennaro Nuzzo; Felice Giuliante; Francesco Ardito; Ivo Giovannini; Luca Aldrighetti; Giulio Belli; Fabrizio Bresadola; Fulvio Calise; Raffaele Dalla Valle; Davide F D'Amico; Leandro Gennari; Stefano M Giulini; Alfredo Guglielmi; Elio Jovine; Riccardo Pellicci; Heinrich Pernthaler; Antonio D Pinna; Stefano Puleo; Guido Torzilli; Lorenzo Capussotti; Umberto Cillo; Giorgio Ercolani; Massimo Ferrucci; Laura Mastrangelo; Nazario Portolani; Carlo Pulitanò; Dario Ribero; Andrea Ruzzenente; Vincenzo Scuderi; Bruno Federico
Journal:  Arch Surg       Date:  2012-01

9.  Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value?

Authors:  Mohamed Abdel Wahab; Ahmad Mohammad Sultan; Tarek Salah; Omar Fathy; Gamal Elebidy; Mohamed Elshobary; Osama Shiha; Ahmed Abdul Rauf; Mohamed Elhemaly; Nabieh El-Ghawalby
Journal:  Hepatogastroenterology       Date:  2012 Mar-Apr

10.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

View more
  41 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Time to Recurrence After Surgical Resection and Survival After Recurrence Among Patients with Perihilar and Distal Cholangiocarcinomas.

Authors:  Yoshitsugu Nakanishi; Keisuke Okamura; Takahiro Tsuchikawa; Toru Nakamura; Takehiro Noji; Toshimichi Asano; Aya Matsui; Kimitaka Tanaka; Soichi Murakami; Yuma Ebihara; Yo Kurashima; Hajime Narasaki; Toraji Amano; Toshiaki Shichinohe; Satoshi Hirano
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

3.  Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma.

Authors:  Laura L Dover; Robert A Oster; Andrew M McDonald; Derek A DuBay; Thomas N Wang; Rojymon Jacob
Journal:  HPB (Oxford)       Date:  2016-08-16       Impact factor: 3.647

Review 4.  Multimodality Management of Localized Biliary Cancer.

Authors:  Nadia Ashai; Preethi Prasad; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2019-05-29

5.  Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma.

Authors:  J Lee; S H Kang; O K Noh; M Chun; Y-T Oh; B-W Kim; S-W Kim
Journal:  Clin Transl Oncol       Date:  2017-12-18       Impact factor: 3.405

6.  Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection.

Authors:  Víctor Molina; Jaime Sampson; Joana Ferrer; Alba Díaz; Juan Ramon Ayuso; Santiago Sánchez-Cabús; Josep Fuster; Juan Carlos García-Valdecasas
Journal:  Langenbecks Arch Surg       Date:  2016-12-23       Impact factor: 3.445

7.  Pulmonary Metastasis After Resection of Cholangiocarcinoma: Incidence, Resectability, and Survival.

Authors:  Mihoko Yamada; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Masato Nagino
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

8.  Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases.

Authors:  Stefan Buettner; Jeroen L A van Vugt; Marcia P Gaspersz; Robert J S Coelen; Eva Roos; Tim A Labeur; Georgios A Margonis; Cecilia G Ethun; Shishir K Maithel; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley A Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Jan N M IJzermans; Thomas M van Gulik; Timothy M Pawlik; Bas Groot Koerkamp
Journal:  HPB (Oxford)       Date:  2017-05-23       Impact factor: 3.647

Review 9.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08

10.  Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease.

Authors:  Cecilia G Ethun; Alexandra G Lopez-Aguiar; Douglas J Anderson; Andrew B Adams; Ryan C Fields; Maria B Doyle; William C Chapman; Bradley A Krasnick; Sharon M Weber; Joshua D Mezrich; Ahmed Salem; Timothy M Pawlik; George Poultsides; Thuy B Tran; Kamran Idrees; Chelsea A Isom; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Kenneth Cardona; Shishir K Maithel
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.